کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2900086 1173317 2015 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants : Relation to Atherosclerotic Risk Factors
ترجمه فارسی عنوان
بروز انفارکتوس میوکارد و مرگ عروقی در سالمندان مبتلا به فیبریلاسیون دهلیزی با استفاده از ضد انعقاد: ارتباط با عوامل خطر آترواسکلروزی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی

BACKGROUNDRecent findings suggest that patients with atrial fibrillation (AF), in addition being at thromboembolic risk, are at risk of myocardial infarction (MI). Our aim was to investigate predictors of MI and cardiovascular death in a cohort of patients with AF who were taking anticoagulants.METHODSWe prospectively followed up 1,019 patients with AF for a median of 33.7 months (3,223 person-years). All patients were treated with oral vitamin K antagonists. Primary outcome was a composite end point of cardiovascular events (CVEs) including fatal/nonfatal MI, cardiac revascularization, and cardiovascular death.RESULTSThe mean age of the patients was 73.2 years, and 43.8' were women. At follow-up, 111 CVEs (3.43'/y) had occurred: 47 fatal-nonfatal MI/revascularization and 64 cardiovascular deaths. In addition, 31 stroke/transient ischemic attacks (0.96'/y) were recorded. Patients experiencing CVEs were older (P < .001) and had a higher prevalence of metabolic syndrome (MetS) (P = .005), heart failure (P = .001), and prior cardiac (P < .001) and cerebrovascular events (P < .001). On a Cox proportional hazard analysis, age (hazard ratio [HR], 1.083; 95' CI, 1.053-1.113; P < .001), smoking (HR, 2.158; 95' CI, 1.193-3.901; P = .011), history of cerebrovascular (HR, 1.704; 95' CI, 1.119-2.597; P = .013) and cardiac (HR, 1.658; 95' CI, 1.105-2.489; P = .015) events, MetS (HR, 1.663; 95' CI, 1.107-2.499; P = .014), heart failure (HR, 1.584; 95' CI, 1.021-2.456; P = .040), and male sex (HR, 1.499; 95' CI, 1.010-2.223; P = .044) predicted CVEs.CONCLUSIONSPatients with AF still experience a high rate of CVEs despite receiving anticoagulant treatment. MetS is a common clinical feature in patients with AF, which increases the risk of CVEs. A holistic approach is needed to reduce the cardiovascular risk in patients with AF.TRIAL REGISTRYClinicalTrials.gov; No.: NCT01882114; URL: www.clinicaltrials.gov

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Chest - Volume 147, Issue 6, June 2015, Pages 1644–1650
نویسندگان
, , , , , , , , , , , ,